Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 4.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 860,096 shares of the company’s stock after selling 35,594 shares during the period. Pictet Asset Management Holding SA owned approximately 1.79% of Mirum Pharmaceuticals worth $35,565,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in MIRM. Lord Abbett & CO. LLC purchased a new position in Mirum Pharmaceuticals in the third quarter valued at about $28,913,000. State Street Corp increased its stake in Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after purchasing an additional 297,511 shares in the last quarter. Erste Asset Management GmbH purchased a new position in Mirum Pharmaceuticals in the 3rd quarter valued at approximately $10,136,000. Raymond James Financial Inc. acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $10,611,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Mirum Pharmaceuticals by 162.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company’s stock worth $7,317,000 after purchasing an additional 109,585 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $45.99 on Monday. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -22.77 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company’s 50-day moving average is $48.01 and its two-hundred day moving average is $43.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on MIRM. Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th. HC Wainwright raised their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a report on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $58.20.

Insider Activity

In other news, SVP Jolanda Howe sold 750 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the transaction, the senior vice president now owns 2,926 shares of the company’s stock, valued at $125,291.32. This represents a 20.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Peetz sold 27,279 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at $6,129,318.61. This represents a 16.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 133,679 shares of company stock valued at $6,007,081 over the last quarter. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.